genXone (WSE:GX1) First Quarter 2025 Results
Key Financial Results
- Revenue: zł427.1k (up 32% from 1Q 2024).
- Net loss: zł732.3k (loss narrowed by 16% from 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
genXone shares are up 6.4% from a week ago.
Risk Analysis
You still need to take note of risks, for example - genXone has 3 warning signs we think you should be aware of.
If you're looking to trade genXone, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:GX1
genXone
Operates in the biotechnology industry in Poland and internationally.
Flawless balance sheet low.
Market Insights
Community Narratives
